Opthea Limited Sponsored ADR (OPT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Opthea Limited is set to showcase its promising treatment for wet age-related macular degeneration, sozinibercept, at the upcoming FLORetina Congress in Italy. The drug, being tested in pivotal Phase 3 trials, aims to enhance the efficacy of existing therapies and improve vision outcomes. This presentation positions Opthea as a key player in advancing retinal disease treatments.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
